Immix Biopharma Inc
NASDAQ:IMMX

Watchlist Manager
Immix Biopharma Inc Logo
Immix Biopharma Inc
NASDAQ:IMMX
Watchlist
Price: 4.95 USD -2.94% Market Closed
Market Cap: 260.8m USD

Immix Biopharma Inc
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Immix Biopharma Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Immix Biopharma Inc
NASDAQ:IMMX
Total Equity
$13.3m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Equity
-$2.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$21.5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
2%
Amgen Inc
NASDAQ:AMGN
Total Equity
$9.6B
CAGR 3-Years
38%
CAGR 5-Years
-3%
CAGR 10-Years
-10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$17.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
34%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$31B
CAGR 3-Years
13%
CAGR 5-Years
25%
CAGR 10-Years
25%
No Stocks Found

Immix Biopharma Inc
Glance View

Market Cap
260.8m USD
Industry
Biotechnology

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the development of therapies for patients with cancer and inflammatory diseases. The company is developing a class of tissue-specific therapeutics (TSTx) in oncology and inflammation. The Company’s lead asset, IMX-110, is is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology, which is delivered into the TME. IMX-110, is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor.

IMMX Intrinsic Value
1.65 USD
Overvaluation 67%
Intrinsic Value
Price

See Also

What is Immix Biopharma Inc's Total Equity?
Total Equity
13.3m USD

Based on the financial report for Dec 31, 2024, Immix Biopharma Inc's Total Equity amounts to 13.3m USD.

What is Immix Biopharma Inc's Total Equity growth rate?
Total Equity CAGR 3Y
-10%

Over the last year, the Total Equity growth was -19%. The average annual Total Equity growth rates for Immix Biopharma Inc have been -10% over the past three years .

Back to Top